# Research Loop Progress

## Current Session: h49-h59 (2026-01-31)

### Session Summary

**Agent Role:** Research Executor
**Status:** Completed (9 hypotheses tested)
**Hypotheses Tested:**
- h49: Gene Expression → Drug Mapping Pipeline - **VALIDATED**
- h50: Rare Skin Disease Baseline Evaluation - **VALIDATED**
- h51: Gene Module Similarity for Disease Matching - **INVALIDATED**
- h52: Meta-Confidence Model for Prediction Reliability - **VALIDATED**
- h53: Skin Disease Name Mapping Expansion - **VALIDATED**
- h54: Production Meta-Confidence Pipeline - **VALIDATED**
- h56: Cancer Category Analysis Deep Dive - **VALIDATED**
- h58: 'Other' Category Subcategorization - **VALIDATED**
- h59: Gastrointestinal Disease Failure Analysis - **VALIDATED**

### MAJOR DISCOVERIES

1. **Gastrointestinal is a CRITICAL blind spot** (5% hit rate)
   - Root cause: kNN neighbors are NOT other GI diseases
   - Node2Vec doesn't capture organ/function similarity
   - 28% of GI drugs are GI-specific (PPIs, hepatitis antivirals)

2. **Extended categories reveal clear performance tiers:**
   - ★★★ (>80%): Endocrine, Autoimmune, Dermatological, Psychiatric
   - ★★ (60-80%): Infectious, Respiratory, Cancer, Ophthalmic
   - ⚠ (<40%): Hematological, Musculoskeletal, Renal
   - ❌ (5%): Gastrointestinal

3. **Gene Jaccard is worse than Node2Vec** (-14.71 pp)

4. **Meta-confidence tiering works** (HIGH tier: 100% hit rate)

### Deliverables Created

1. **Gene Expression → Drug Pipeline**: `scripts/gene_expression_drug_mapping.py`
2. **Meta-Confidence Model**: `models/meta_confidence_model.pkl`, `meta_confidence_helper.py`
3. **26 Manual Skin Disease MESH Mappings**
4. **16-Category Classification System**

### Remaining Hypotheses

1. h60: Update Meta-Confidence Model with Extended Categories (Priority 2)
2. h57: Metabolic Disease Deep Dive (Priority 2)
3. h55: GEO Gene Expression Data Integration (Priority 3)
4. h16: Clinical Trial Phase Features (Priority 20)

### Production Recommendations

1. **EXCLUDE or FLAG GI predictions** - 5% success is worse than random
2. **Prioritize endocrine/autoimmune/dermatological/psychiatric** - >80% hit rate
3. **Use HIGH confidence tier** - 100% hit rate
4. **Deploy extended categories** in meta-confidence model
5. **Accept kNN limitation** for organ-specific disease categories

### Session Statistics

- Hypotheses tested: 9
- Validated: 8
- Invalidated: 1
- New hypotheses generated: 7 (h53-h60)
- Critical finding: GI blind spot identified and explained
